SHANGHAI – Zai Lab Inc., of Shanghai, has received $30 million in financing from a group of international venture capital investors, led by the well-respected Qiming Venture Partners LLC, headquartered in Hong Kong. The series A funding will support Zai's pursuit of its "virtual" business model, and the in-licensing and developing of innovative drugs for global markets as well as China.